Editorial: Inflammation and immune diseases: Molecular targets for pathogenesis and treatment.

Wu FR
Frontiers in pharmacology · 2023 · doi:10.3389/fphar.2023.1174965 · PMID:37021046 · PMC10067895
OA: gold CC-BY-4.0
📄 Open PDF Full text JSON View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash+body, 2026-08-28 ⓘ

This editorial acknowledges the guest editors, contributors, and publisher for organizing a Research Topic on molecular targets for pathogenesis and treatment in inflammation and immune diseases.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-08-28 · read from full text ⓘ

This editorial serves as a concluding remark for a Research Topic titled "Inflammation and immune diseases: Molecular targets for pathogenesis and treatment," published in Frontiers in Pharmacology. The authors express gratitude to the guest editors, contributors, and the publisher for their roles in organizing and facilitating the collection of manuscripts on this subject. No original research data or specific clinical findings are presented, as the text functions primarily as an acknowledgment of the collaborative effort behind the special issue. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 1,062 characters · extracted from epmc-fulltextxml · 4 sections · click to expand

Ack

In the end, I would like to first thank our guest editors (Ang Gao, Feng-lai Yuan), because they worked very hard to organize the Research Topic and review manuscripts assigned to them. Second, I would like to thank all the contributors who submitted their great work to this Research Topic. Last but not the least, we would like to thank Frontier in Pharmacology for giving us this opportunity to learn a great deal from this Research Topic.

Author

The author confirms being the sole contributor of this work and has approved it for publication.

Conflict

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’S

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: epmc-fulltextxml ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-09-06T09:34:12.023084+00:00
License: CC-BY-4.0 · commercial use OK · attribution required
Per Europe PMC